Tomatoes and lycopene: a review without a clear blood-pressure benefit
A 34-study review found no significant systolic or diastolic pressure effect despite an oxidative-stress marker finding.

Illustrative food image, not a photograph of the study intervention.
The question was broader than pressure
This systematic review investigated lycopene and tomato consumption across several cardiovascular risk factors. The authors searched PubMed, Web of Science, and Scopus through November 2022 for eligible randomized controlled trials. Of 27,438 records initially identified, 34 studies met their eligibility criteria. Those counts describe the overall review, not a statement that all 34 studies contributed blood-pressure measurements. The outcomes included lipids, glycemic markers, blood pressure, inflammation, oxidative stress, and body weight. Keeping that broad scope visible prevents the review's total study count from being mistaken for the amount of evidence behind any one endpoint.
Zamani M, Behmanesh Nia F, Ghaedi K, Mohammadpour S et al.. Current pharmaceutical design, 2023. PMID 37496241 · DOI
Neither pressure endpoint was significant
The abstract reports no significant effect of lycopene and tomato consumption on either systolic or diastolic blood pressure. It does not provide a pooled blood-pressure change or a confidence interval for those endpoints. A faithful summary therefore cannot supply a millimeter-of-mercury estimate or promise a particular reduction. The authors used heterogeneity testing and weighted mean differences with 95% confidence intervals in their analyses, but the pressure-specific numbers are not included in the abstract. The result supports caution about a pressure-lowering claim; it does not establish that every tomato intervention has exactly zero effect under every condition.
Zamani M, Behmanesh Nia F, Ghaedi K, Mohammadpour S et al.. Current pharmaceutical design, 2023. PMID 37496241 · DOI
A biomarker result is a different result
The significant finding highlighted in the abstract concerned malondialdehyde, abbreviated MDA. Lycopene consumption reduced this marker, which the authors discuss in relation to oxidative stress. That finding must remain attached to its own endpoint rather than being used to imply that blood pressure also improved. The same abstract explicitly lists systolic and diastolic pressure among outcomes without significant effects. It also reports no significant effects on several lipid, glycemic, inflammatory, and body-weight outcomes. A favorable result for one marker cannot replace the separate result for pressure in an article focused on hypertension evidence.
Zamani M, Behmanesh Nia F, Ghaedi K, Mohammadpour S et al.. Current pharmaceutical design, 2023. PMID 37496241 · DOI
What remains unresolved
The authors call for further studies with longer durations and different doses to confirm their findings. That is a limit on what this review can settle, not a basis for choosing a dose for readers. Its intervention scope includes both lycopene and tomato consumption, so the abstract does not establish a pressure effect for a particular tomato dish. Nor does its list of risk-factor outcomes demonstrate fewer cardiovascular events. The clearest reading stays close to the reported endpoints: a reduction in MDA with lycopene, alongside no significant pooled effect on systolic or diastolic blood pressure in the abstract's summary.
Zamani M, Behmanesh Nia F, Ghaedi K, Mohammadpour S et al.. Current pharmaceutical design, 2023. PMID 37496241 · DOI